Health and Healthcare

Pfizer : PFE

All Pfizer Articles

1490 Articles

Jon C. Ogg | Jan 9, 2015 at 11:25 AM EST

The Bullish and Bearish Case for Pfizer in 2015

One key consideration for the year ahead is that the Pfizer of 2016 or 2017 is likely to be night…

Jon C. Ogg | Jan 8, 2015 at 8:15 AM EST

The Bullish and Bearish Case for Johnson & Johnson in 2015

One key consideration for the year ahead is that Johnson & Johnson raised its dividends again and managed to have…

Paul Ausick | Dec 26, 2014 at 4:01 PM EST

The 4 Stocks That Pushed Friday’s Market to New Highs

thinkstockDecember 26, 2014: Markets opened higher on Friday on a morning when it was difficult to find any market-moving news…

Jon C. Ogg | Dec 23, 2014 at 11:25 AM EST

Great Dividends: Meet the Preliminary 2015 Dogs of the Dow

With investors loving dividends so much, 24/7 always tries to take a look at what the Dogs of the Dow…

Jon C. Ogg | Dec 10, 2014 at 10:35 AM EST

What a Generic Celebrex Means for Pfizer and for Actavis

While this was generally a known event coming down the pipe, arthritis drug Celebrex now has a generic competitor in…

Paul Ausick | Dec 5, 2014 at 4:01 PM EST

The 4 Stocks That Carried the Market on Friday

thinkstockDecember 4, 2014: Markets opened higher on Friday after the federal government released a better-than-expected report on employment. Job gains…

Lee Jackson | Dec 3, 2014 at 8:25 AM EST

2014’s Underperforming Large-Cap Stocks That Could Be 2015 Winners

The U.S. equity market is still a great place to be, and the analysts at Jefferies may have a good…

Lee Jackson | Dec 1, 2014 at 8:25 AM EST

Analyst’s 4 Stocks to Buy With Imminent Catalysts

A new report from Jefferies focuses on four stocks to buy that have impending events that could make a difference…

Paul Ausick | Nov 25, 2014 at 4:01 PM EST

The 4 Stocks That Lifted the DJIA

thinkstockNovember 25, 2014: Markets opened higher on Tuesday but the gains were small heading into the long weekend. The second…

Paul Ausick | Nov 18, 2014 at 9:10 AM EST

Companies Spending the Most on R&D

For the third consecutive year, the company spending the most on research and development (R&D) was Germany's Volkswagen.

Chris Lange | Oct 27, 2014 at 12:40 PM EDT

Pain Therapeutics and Durect Stung by Pfizer Move

Durect and Pain Therapeutics have been stung by Pfizer's decision to discontinue to develop Remoxy.

Paul Ausick | Oct 24, 2014 at 4:01 PM EDT

The 4 DJIA Stocks That Boosted the Market

thinkstockOctober 24, 2014: Markets opened slightly higher on Friday, and following a short trip below the break-even line, marched higher…

Jon C. Ogg | Oct 24, 2014 at 8:05 AM EDT

Pfizer Stock Buyback Plan Just Too Large to Ignore — It Is on Viagra

Pfizer's new buyback is simply too large and too significant to ignore, and it might jokingly be called "on Viagra."

Paul Ausick | Oct 16, 2014 at 4:01 PM EDT

The 4 Stocks That Held the DJIA Down

thinkstockOctober 16, 2014: Markets opened lower on Thursday following a sharp drop in crude oil prices overnight and a better-than-expected…

Jon C. Ogg | Oct 10, 2014 at 9:30 AM EDT

Short Sellers Getting Smart in Defensive High-Yield Dividend Stocks

Short sellers have decided to get out of some of the go-to defensive stocks with high-dividend yields in late September.

1 … 62 63 64 65 66 … 100

Pfizer : PFE

All Pfizer Articles

The Bullish and Bearish Case for Pfizer in 2015

The Bullish and Bearish Case for Johnson & Johnson in 2015

The 4 Stocks That Pushed Friday’s Market to New Highs

Great Dividends: Meet the Preliminary 2015 Dogs of the Dow

What a Generic Celebrex Means for Pfizer and for Actavis

The 4 Stocks That Carried the Market on Friday

2014’s Underperforming Large-Cap Stocks That Could Be 2015 Winners

Analyst’s 4 Stocks to Buy With Imminent Catalysts

The 4 Stocks That Lifted the DJIA

Companies Spending the Most on R&D

Pain Therapeutics and Durect Stung by Pfizer Move

The 4 DJIA Stocks That Boosted the Market

Pfizer Stock Buyback Plan Just Too Large to Ignore — It Is on Viagra

The 4 Stocks That Held the DJIA Down

Short Sellers Getting Smart in Defensive High-Yield Dividend Stocks

Suze Orman to 54-Year-Old With $600,000: Skip the 1.5% Fee and Manage It Yourself

Forget the Labor Market Noise: This Essential Business Utility Stock Is the Ultimate “Set-It-and-Forget-It” Cash Cow

3 Stocks With a Yield Over 6% For Passive Income Investors

Suze Orman to 54-Year-Old With $600,000: Skip the 1.5% Fee and Manage It Yourself

A $2.5 Million 401(k) at 73 Can Still Cost You Six Figures Without These 3 Moves

Suze Orman to 54-Year-Old With $600,000: Skip the 1.5% Fee and Manage It Yourself

Forget the Labor Market Noise: This Essential Business Utility Stock Is the Ultimate “Set-It-and-Forget-It” Cash Cow

Pfizer : PFE

All Pfizer Articles

The Bullish and Bearish Case for Pfizer in 2015

The Bullish and Bearish Case for Johnson & Johnson in 2015

The 4 Stocks That Pushed Friday’s Market to New Highs

Great Dividends: Meet the Preliminary 2015 Dogs of the Dow

What a Generic Celebrex Means for Pfizer and for Actavis

The 4 Stocks That Carried the Market on Friday

2014’s Underperforming Large-Cap Stocks That Could Be 2015 Winners

Analyst’s 4 Stocks to Buy With Imminent Catalysts

The 4 Stocks That Lifted the DJIA

Companies Spending the Most on R&D

Pain Therapeutics and Durect Stung by Pfizer Move

The 4 DJIA Stocks That Boosted the Market

Pfizer Stock Buyback Plan Just Too Large to Ignore — It Is on Viagra

The 4 Stocks That Held the DJIA Down

Short Sellers Getting Smart in Defensive High-Yield Dividend Stocks

Suze Orman to 54-Year-Old With $600,000: Skip the 1.5% Fee and Manage It Yourself

Forget the Labor Market Noise: This Essential Business Utility Stock Is the Ultimate “Set-It-and-Forget-It” Cash Cow

3 Stocks With a Yield Over 6% For Passive Income Investors

Featured Reads

Suze Orman to 54-Year-Old With $600,000: Skip the 1.5% Fee and Manage It Yourself

A $2.5 Million 401(k) at 73 Can Still Cost You Six Figures Without These 3 Moves